Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06033820

Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

A Prospective, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of Zanubrutinib, Lenalidomide With R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Sponsor: RenJi Hospital

Conditions Diffuse Large B Cell Lymphoma Refractory Diffuse Large B-cell Lymphoma Recurrent

Interventions ZR2-ICE

Updated 5 times since 2023 Last updated: Mar 11, 2024 Started: Oct 12, 2023 Primary completion: Jun 30, 2025 Completion: Jun 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Diffuse Large B Cell Lymphoma Refractory and Diffuse Large B-cell Lymphoma Recurrent, this trial is actively recruiting participants. The trial is conducted by RenJi Hospital and has accumulated 5 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Nov 2023 — Apr 2024 [monthly]

Not Yet Recruiting PHASE2
Oct 2023 — Nov 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

RenJi Hospital

Data source: RenJi Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China